03/31/2026
Groundbreaking Sickle Cell Disease Gene Therapy
High school teacher Marcus Mitchell, 35, is the first adult at Duke University Hospital to undergo this gene therapy aimed at curing sickle cell disease.
Duke Health is pioneering a groundbreaking FDA-approved gene therapy (Lyfgenia) that treats sickle cell disease by using a patient’s own stem cells, removing the need for a donor. As one of the first centers in the Southeast to offer this, it offers a curative option for adults and children, reducing severe pain and hospitalizations.
Key Aspects of the Treatment at Duke:
The Procedure: It is a one-time therapy where the patient’s own stem cells are modified to produce healthy red blood cells.
Significance: It eliminates the need for a matched sibling donor, which is a significant barrier for most patients.
Patient Impact: The therapy acts as a functional cure, allowing patients to live without debilitating pain and crisis.
Clinical Leadership: Duke has been actively involved in the clinical trials, including treating the first adult patient in North Carolina to receive this type of therapy, as detailed in this story from wfmynews2.
Ongoing Research: The Doris Duke Foundation has also funded foundational research that helped lead to similar breakthroughs, including CRISPR-based cures.
Risks and Considerations:
While promising, the therapy does carry risks, including a "black box" warning for hematologic malignancy (blood cancer), requiring lifelong monitoring for recipients. Duke Health is pioneering a groundbreaking FDA-approved gene therapy (Lyfgenia) that treats sickle cell disease by using a patient’s own stem cells, removing the need for a donor. As one of the first centers in the Southeast to offer this, it offers a curative option for adults and children, reducing severe pain and hospitalizations.
Key Aspects of the Treatment at Duke:
The Procedure: It is a one-time therapy where the patient’s own stem cells are modified to produce healthy red blood cells.
Significance: It eliminates the need for a matched sibling donor, which is a significant barrier for most patients.
Patient Impact: The therapy acts as a functional cure, allowing patients to live without debilitating pain and crisis.
Clinical Leadership: Duke has been actively involved in the clinical trials, including treating the first adult patient in North Carolina to receive this type of therapy, as detailed in this story from wfmynews2.
Ongoing Research: The Doris Duke Foundation has also funded foundational research that helped lead to similar breakthroughs, including CRISPR-based cures.
Risks and Considerations:
While promising, the therapy does carry risks, including a "black box" warning for hematologic malignancy (blood cancer), requiring lifelong monitoring for recipients.
https://youtu.be/FCUHGSEcnog?si=lF-DdUOGKAChT6m5
